ArticleBritish journal of haematology2026
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.
Sari Kytölä et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.